AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31597083
Drug: XC8 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XC8 (10 mg)
Trial: 31597083
Drug: XC8 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XC8 (50 mg)
Trial: 31597083
Drug: XC8 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XC8 (200 mg)
Trial: 31597083
Drug: XC8 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XC8 (all doses)
Trial: 30293349
Drug: Intracytoplasmic sperm
RxNorm normalized name: herring sperm DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracytoplasmic sperm injection (ICSI) for MMAF patients
Trial: 30293349
Drug: Intracytoplasmic sperm
RxNorm normalized name: herring sperm DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracytoplasmic sperm injection (ICSI) for OA patients
Trial: 22117732
Drug: Moderately rough
RxNorm normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately rough implants (TiUnite)
Trial: 22117732
Drug: Minimally rough
RxNorm normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally rough implants (turned)
Trial: 21048171
Drug: Radial shock-wave
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radial shock-wave therapy (Group II, n = 48)
Trial: 7326866
Drug: Dexamethasone acetate
RxNorm normalized name: Dexamethasone Acetate
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone acetate at 2 of 3 mg/day for 9 or 13 weeks
Trial: 24969283
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg of rifaximin twice a day for 12 weeks
Trial: 24969283
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg of rifaximin
Trial: 17502725
Drug: Immediate PAIG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate PAIG injections (weeks 0 and 6)
Trial: 17502725
Drug: Delayed PAIG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed PAIG injections (weeks 12 and 18)
Trial: 17502725
Drug: Both immediate
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both immediate and delayed PAIG injections
Trial: 9932756
Drug: Patient-controlled sedation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled sedation using propofol (10 mg/ml) and alfentanil (25 microg/ml)
Trial: 9932756
Drug: Intravenous diazemuls
RxNorm normalized name: Diazemuls
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous diazemuls (10-20 mg) and pethidine (50 mg)
Trial: 7804031
Drug: Selenium concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium concentration and glutathione peroxidase activity before and during treatment with cytostatics
Trial: 2231320
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) hydralazine thrice daily, daily doses of 75, 150, or 300 mg
Trial: 2231320
Drug: Extended-release (ER)
RxNorm normalized name: Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release (ER) hydralazine twice daily, daily doses of 75, 150, or 300 mg
Trial: 2231320
Drug: Extended-release (ER)
RxNorm normalized name: Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release (ER) hydralazine once daily, daily doses of 75, 150, or 300 mg
Trial: 2231320
Drug: Concomitant beta-blocker
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant beta-blocker (BB) therapy
Trial: 2231320
Drug: Hydralazine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydralazine treatment
Trial: 31481362
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (MT) focusing on parental singing tailored to infant responses during NICU and/or postdischarge 6-month period
Trial: 29947285
Drug: Ginger aromatherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger aromatherapy (inhalation of essential oil of ginger)
Trial: 27816672
Drug: CC (41
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC (41 participants)
Trial: 27816672
Drug: THS 2.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THS 2.2 and CC (80 and 41 participants respectively)
Trial: 24268387
Drug: omega-3 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omega-3 (1 g, 3 times daily)
Trial: 22902139
Drug: Instrument-assisted spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instrument-assisted spinal manipulative therapy (SMT)
Trial: 20230454
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg lidocaine in 125 mL of saline once a week for 4 weeks
Trial: 18942422
Drug: New Russian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New Russian oral ribavirin-containing agents
Trial: 2082489
Drug: Aspirin (330
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (330 mg) and dipyridamole (75 mg) t.i.d.
Trial: 7436817
Drug: Sinemet 20/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinemet 20/100 (20 mg of carbidopa to 100 mg of levodopa)
Trial: 7436817
Drug: Sinemet 10/100
RxNorm normalized name: Sinemet 10/100 Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinemet 10/100 (10 mg of carbidopa to 100 mg of levodopa)
Trial: 7436817
Drug: Levodopa alone
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa alone (100 mg)
Trial: 31192423
Drug: Multimodal occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal occupational specific treatment for exhaustion disorder
Trial: 28129020
Drug: Brinzolamide/Brimonidine Fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brinzolamide/Brimonidine Fixed Combination (BBFC) 1%/0.2% 3 times daily
Trial: 11384568
Drug: Timolol maleate
RxNorm normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol maleate 0.5% twice daily
Trial: 25905534
Drug: Hot glutamate
RxNorm normalized name: glutamate
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hot glutamate solution (48°C)
Trial: 25905534
Drug: Cold glutamate
RxNorm normalized name: glutamate
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cold glutamate solution (3°C)
Trial: 25905534
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline (neutral solution at 36°C)
Trial: 25905534
Drug: Cold solutions
RxNorm normalized name: menthol Topical Solution [Cold Spot]
DrugBank: Chlorpheniramine (DB01114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold solutions
Trial: 21343835
Drug: Low-dose ZENPEP
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ZENPEP (7 × 5000 lipase units per day)
Trial: 21343835
Drug: High-dose ZENPEP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ZENPEP (7 × 20,000 lipase units per day)
Trial: 21343835
Drug: High-dose ZENPEP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ZENPEP (7 × 20,000 lipase units per day) in patients with baseline CFA < 90% (n = 33)
Trial: 21343835
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of ZENPEP
Trial: 594788
Drug: Methyclothiazide 10
RxNorm normalized name: Methyclothiazide
DrugBank: Methyclothiazide (DB00232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyclothiazide 10 mg daily
Trial: 594788
Drug: Methyclothiazide 5
RxNorm normalized name: methyclothiazide 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyclothiazide 5 mg daily
Trial: 21309619
Drug: Combined psycho-
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined psycho- and pharmacotherapy for patients with co-morbid personality disorders (PDs)
Trial: 21309619
Drug: Combined psycho-
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined psycho- and pharmacotherapy for patients with no personality disorders (PDs)
Trial: 16499796
Drug: 0.75% hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% hyperbaric bupivacaine 1.5 ml with 0.25 ml fentanyl (12.5 microg)
Trial: 16499796
Drug: 0.75% hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% hyperbaric bupivacaine 1.5 ml with 0.25 ml normal saline
Trial: 14679137
Drug: Temozolomide 200
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide 200 mg/m2/day
Trial: 14679137
Drug: Temozolomide 250
RxNorm normalized name: temozolomide 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temozolomide 250 mg/m2/day
Trial: 14679137
Drug: Temozolomide 300
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide 300 mg/m2/day
Trial: 14679137
Drug: Temozolomide 350
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide 350 mg/m2/day
Trial: 14679137
Drug: Temozolomide 300
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide 300 mg/m2/day recommended dose
Trial: 14679137
Drug: Temozolomide (dose-dense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temozolomide (dose-dense regimen)
Trial: 11704117
Drug: Ibuprofen (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (800 mg, three times per day for 10 days)
Trial: 3134518
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment (beta-blocker)
Trial: 30144146
Drug: Low Oral
RxNorm normalized name: Milkflow oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Oral Health Literacy (OHL) defined as BREALD-30 ≤ 21
Trial: 30144146
Drug: Low Oral
RxNorm normalized name: Milkflow oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Oral Health Literacy (OHL)
Trial: 30144146
Drug: Higher Oral
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher Oral Health Literacy (OHL)
Trial: 28795232
Drug: Conventional Doyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Doyle intranasal silicone splint (Group 1)
Trial: 24002152
Drug: Topical adapalene
RxNorm normalized name: adapalene Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical adapalene 0.1% gel
Trial: 24002152
Drug: Topical benzoyl
RxNorm normalized name: benzoyl peroxide Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical benzoyl peroxide 2.5% gel
Trial: 21359582
Drug: Insulin during
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin during hospitalisation followed by conventional glucose control (group 2)
Trial: 21359582
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (group 3)
Trial: 14594526
Drug: Pioglitazone 30
RxNorm normalized name: pioglitazone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg for 20 weeks
Trial: 14594526
Drug: Pioglitazone 30
RxNorm normalized name: pioglitazone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg for 12 weeks followed by 45 mg for 8 weeks
Trial: 14594526
Drug: Pioglitazone 45
RxNorm normalized name: pioglitazone 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 45 mg for 20 weeks
Trial: 10918402
Drug: Foscarnet at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foscarnet at dose level I (60/30 mg/kg/day)
Trial: 10918402
Drug: Foscarnet at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foscarnet at dose level II (120/60 mg/kg/day)
Trial: 10918402
Drug: Foscarnet at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foscarnet at dose level III (120/90 mg/kg/day)
Trial: 10918402
Drug: Foscarnet at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foscarnet at dose level IV (120/120 mg/kg/day)
Trial: 10918402
Drug: Foscarnet at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foscarnet at dose levels I and II
Trial: 10918402
Drug: Foscarnet at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foscarnet at dose levels III and IV
Trial: 10918402
Drug: Foscarnet at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foscarnet at dose levels I-II
Trial: 10918402
Drug: Foscarnet at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foscarnet at dose levels III-IV
Trial: 10918402
Drug: Foscarnet (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foscarnet (all dose levels)
Trial: 3911735
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg hydrochlorothiazide plus 5 mg amiloride (HCTZ/A)
Trial: 3911735
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg hydrochlorothiazide plus 26 mmol potassium chloride (HCTZ/K)
Trial: 3911735
Drug: HCTZ/K (double
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCTZ/K (double dose: 100 mg/52 mmol)
Trial: 3911735
Drug: HCTZ/A (double
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCTZ/A (double dose: 100 mg/10 mg)
Trial: 3911735
Drug: Both drug
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drug combinations
Trial: 18504760
Drug: Gadobutrol (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadobutrol (1.0 mmol Gd/mL, 15 mL)
Trial: 18504760
Drug: Gadoterate (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadoterate (0.5 mmol Gd/mL, 30 mL)
Trial: 14560166
Drug: Psychoeducational parenting
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducational parenting program (3 weekly sessions + 1-month booster)
Trial: 8898462
Drug: Praziquantel (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel (40 mg/kg body weight)
Trial: 1716644
Drug: Chlorthalidone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (100 mg PO)
Trial: 1716644
Drug: Control (Org
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Org 10172 IV bolus injection of 3250 anti‐Xa units)
Trial: 28333351
Drug: Ciprofloxacin (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (dosage not specified) administered from day 0 to day 14
Trial: 24268209
Drug: Bivalirudin (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin (0.75 mg/kg bolus followed by 1.75 mg/kg/hour infusion for ≥30 minutes prior to PCI and continued for ≥4 hours at 0.25 mg/kg/hour)
Trial: 24268209
Drug: Standard-of-care anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care anticoagulation (heparins at guideline-recommended doses, with or without glycoprotein IIb/IIIa inhibitors)
Trial: 16478762
Drug: 2% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lignocaine gel
Trial: 7717498
Drug: Lubafax gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubafax gel (Control)
Trial: 26954484
Drug: Aged Garlic
RxNorm normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aged Garlic Extract (AGE) 1200 mg daily for 4 weeks
Trial: 17616771
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg Salacia oblonga extract
Trial: 17616771
Drug: 480 mg
RxNorm normalized name: magaldrate 480 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 480 mg Salacia oblonga extract
Trial: 12503274
Drug: Losec, 40
RxNorm normalized name: PriLOSEC, 40 mg oral delayed release capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losec, 40 mg (omeprazole)
Trial: 12503274
Drug: famotidine, 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famotidine, 80 mg (Quamatel)
Trial: 9793352
Drug: Intrapleural analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapleural analgesia with 75 mg of bupivacaine 0.50% administered through a peridural catheter at 8-hour intervals for up to three times
Trial: 20642580
Drug: CLA 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLA 4.5 g/day
Trial: 17419879
Drug: Plant sterol
RxNorm normalized name: plant sterol complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterol esters (PSE) in capsule form (1.3 grams of PSE/day)
Trial: 9419519
Drug: Spiral CT
RxNorm normalized name: Trichinella spiralis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spiral CT with 150 ml diatrizoate meglumine
Trial: 9419519
Drug: Spiral CT
RxNorm normalized name: Trichinella spiralis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spiral CT with 75 ml diatrizoate meglumine
Trial: 9419519
Drug: Spiral CT
RxNorm normalized name: Trichinella spiralis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spiral CT with 100 ml diatrizoate meglumine
Trial: 9419519
Drug: Dynamic CT
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic CT with 150 ml diatrizoate meglumine
Trial: 2098573
Drug: Flurbiprofen 100
RxNorm normalized name: flurbiprofen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 100 mg twice a day for three months
Trial: 30718622
Drug: Baduanjin exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baduanjin exercise (5 × 60 min/weekly for 12 weeks)
Trial: 25646406
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (70μg/2800 IU cholecalciferol daily for 52 weeks)
Trial: 21879101
Drug: Encapsulated caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Encapsulated caffeine (134 mg)
Trial: 15716246
Drug: Multifactorial intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifactorial intervention (medical, physiotherapy, and occupational therapy)
Trial: 31852579
Drug: 6-month treatment
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month treatment
Trial: 31852579
Drug: 3-month treatment
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-month treatment
Trial: 30250407
Drug: Experimental occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental occupational therapy (OT) intervention
Trial: 26865854
Drug: ABT 160
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT 160 mg + LPV/r
Trial: 26865854
Drug: ABT 320
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT 320 mg + LPV/r
Trial: 24881208
Drug: Presurgical nasoalveolar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presurgical nasoalveolar molding (PNAM) treatment prior to operation in group A
Trial: 17134960
Drug: Orlistat (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat (120 mg three times a day) combined with diet
Trial: 2088995
Drug: Oral controlled-release
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral controlled-release morphine (MS Contin Tablets; MSC)
Trial: 2088995
Drug: Previous analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous analgesic regimens
Trial: 31813658
Drug: Pentosan polysulfate
RxNorm normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentosan polysulfate sodium (PPS) monotherapy
Trial: 28560502
Drug: Infiltration treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infiltration treatment
Trial: 24912053
Drug: Strawberry consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strawberry consumption (500 g daily for 30 days)
Trial: 22360383
Drug: Sildenafil (thrice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (thrice daily for 4 weeks)
Trial: 20105143
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment during infancy and childhood
Trial: 18767582
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Danazol (medication group)
Trial: 12777271
Drug: Long-acting risperidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting risperidone 75 mg
Trial: 12777271
Drug: Long-acting risperidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting risperidone (all doses)
Trial: 12870776
Drug: Control (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (50 g glucose without guar)
Trial: 10554499
Drug: Bolus group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus group (15 micrograms.kg‐1 bolus dose + 0.1 microgram.kg‐1.min‐1 infusion, n = 9)
Trial: 10554499
Drug: Non-bolus group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-bolus group (0.1 microgram.kg‐1.min‐1 infusion, n = 8)
Trial: 6847336
Drug: Dextroamphetamine, 15
RxNorm normalized name: Amphetamine-Dextroamphetamine, 15 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine, 15 mg/day